AllianceBernstein
CTMX icon

AllianceBernstein’s CytomX Therapeutics CTMX Stock Holding History

AllianceBernstein’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-49,700
Closed -$133K – 3286
2022
Q1 		$133K Buy
49,700
+200
+0.4% +$768 ﹤0.01% 3078
2021
Q4 		$214K Sell
49,500
-900
-2% -$5.27K ﹤0.01% 3048
2021
Q3 		$257K Sell
50,400
-6,700
-12% -$35.9K ﹤0.01% 3005
2021
Q2 		$361K Buy
57,100
+10,300
+22% +$80.2K ﹤0.01% 2955
2021
Q1 		$362K Sell
46,800
-16,100
-26% -$127K ﹤0.01% 2824
2020
Q4 		$412K Hold
62,900
– – ﹤0.01% 2676
2020
Q3 		$418K Sell
62,900
-1,500
-2% -$11.1K ﹤0.01% 2618
2020
Q2 		$536K Hold
64,400
– – ﹤0.01% 2569
2020
Q1 		$494K Buy
64,400
+5,600
+10% +$39K ﹤0.01% 2360
2019
Q4 		$489K Sell
58,800
-87,837
-60% -$593K ﹤0.01% 2556
2019
Q3 		$1.08M Sell
146,637
-21,350
-13% -$211K ﹤0.01% 2216
2019
Q2 		$1.89M Hold
167,987
– – ﹤0.01% 2008
2019
Q1 		$1.81M Buy
167,987
+69,917
+71% +$1.03M ﹤0.01% 1951
2018
Q4 		$1.48M Hold
98,070
– – ﹤0.01% 2001
2018
Q3 		$1.81M Hold
98,070
– – ﹤0.01% 2016
2018
Q2 		$2.24M Buy
98,070
+23,800
+32% +$608K ﹤0.01% 1830
2018
Q1 		$2.11M Sell
74,270
-7,720
-9% -$220K ﹤0.01% 1780
2017
Q4 		$1.73M Buy
81,990
+8,300
+11% +$172K ﹤0.01% 1950
2017
Q3 		$1.34M Hold
73,690
– – ﹤0.01% 2118
2017
Q2 		$1.14M Buy
73,690
+39,090
+113% +$589K ﹤0.01% 2228
2017
Q1 		$598K Buy
+34,600
New +$455K ﹤0.01% 2477

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein's CTMX Position: Q2 2022 in Review

AllianceBernstein sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 49,700 shares — an estimated $133K sold.

AllianceBernstein first reported a position in CTMX in Q1 2017 and held it in 21 quarters. The position peaked at $2.24M in Q2 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • AllianceBernstein reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 49,700 CytomX Therapeutics shares in Q2 2022, an estimated $133K.
  • AllianceBernstein first reported a position in CytomX Therapeutics in Q1 2017 and held it in 21 quarters.
  • AllianceBernstein's CytomX Therapeutics position peaked at $2.24M in Q2 2018.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.